These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Pleural effusion and pulmonary hypertension in a patient with Parkinson disease treated with cabergoline].
    Author: Haro-Estarriol M, Sabater-Talaverano G, Rodríguez-Jerez F, Obrador-Lagares A, Genís-Batlle D, Sendra-Salillas S.
    Journal: Arch Bronconeumol; 2009 Feb; 45(2):100-2. PubMed ID: 19232272.
    Abstract:
    Cabergoline is a synthetic dopamine agonist used to treat Parkinson disease. The drug occasionally induces pleuropulmonary adverse effects, which manifest as pleural thickening or effusion, interstitial pneumonitis, pulmonary infiltrates, or fibrosis. We report a rare case of pleural effusion and severe pulmonary hypertension in a 79-year-old man with Parkinson disease who had been treated with cabergoline for 1 year. The symptoms disappeared 10 months after the drug was discontinued.
    [Abstract] [Full Text] [Related] [New Search]